AU4765101A - Thioketals and thioethers for inhibiting the expression of vcam-1 - Google Patents
Thioketals and thioethers for inhibiting the expression of vcam-1Info
- Publication number
- AU4765101A AU4765101A AU4765101A AU4765101A AU4765101A AU 4765101 A AU4765101 A AU 4765101A AU 4765101 A AU4765101 A AU 4765101A AU 4765101 A AU4765101 A AU 4765101A AU 4765101 A AU4765101 A AU 4765101A
- Authority
- AU
- Australia
- Prior art keywords
- thioketals
- vcam
- thioethers
- inhibiting
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/20—Carbocyclic rings
- C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/10—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C323/18—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
- C07C323/20—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and singly-bound oxygen atoms bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton with singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
- C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
- C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
- C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US19104600P | 2000-03-21 | 2000-03-21 | |
PCT/US2001/009049 WO2001070757A2 (en) | 2000-03-21 | 2001-03-21 | Thioketals and thioethers for inhibiting the expression of vcam-1 |
Publications (1)
Publication Number | Publication Date |
---|---|
AU4765101A true AU4765101A (en) | 2001-10-03 |
Family
ID=22703910
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU4765101A Pending AU4765101A (en) | 2000-03-21 | 2001-03-21 | Thioketals and thioethers for inhibiting the expression of vcam-1 |
AU2001247651A Ceased AU2001247651B2 (en) | 2000-03-21 | 2001-03-21 | Thioketals and thioethers for inhibiting the expression of vcam-1 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2001247651A Ceased AU2001247651B2 (en) | 2000-03-21 | 2001-03-21 | Thioketals and thioethers for inhibiting the expression of vcam-1 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1289944A2 (en) |
JP (1) | JP2003528109A (en) |
AU (2) | AU4765101A (en) |
CA (1) | CA2403823A1 (en) |
WO (1) | WO2001070757A2 (en) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID23877A (en) * | 1997-05-14 | 2000-05-25 | Atherogenics Inc | COMPOUNDS AND METHODS FOR INCOME OF VCAM-1 EXPRESSION |
AU2002363318B2 (en) * | 2001-10-25 | 2008-09-11 | Atherogenics, Inc. | Compounds and methods for treating transplant rejection |
ITMI20020597A1 (en) | 2002-03-22 | 2003-09-22 | Nicox Sa | DERIVATIVES OF THE PROBUCLE |
US6960683B2 (en) | 2002-07-12 | 2005-11-01 | Atherogenics, Inc. | Salt forms of poorly soluble probucol esters and ethers |
MXPA05007548A (en) | 2003-01-13 | 2005-10-20 | Atherogenics Inc | Process of preparing esters and ethers of probucol and derivatives thereof. |
WO2005102323A2 (en) | 2004-04-20 | 2005-11-03 | Atherogenics, Inc. | Process of preparing esters and ethers of probucol and derivatives thereof |
JP2008505097A (en) * | 2004-07-01 | 2008-02-21 | アセロジエニクス・インコーポレイテツド | Compounds and methods for treating diabetic vascular disease |
US20100004333A1 (en) * | 2004-12-17 | 2010-01-07 | Stocker Roland O | Compositions and methods for treating cardiovascular disorders |
JP2010522762A (en) | 2007-03-26 | 2010-07-08 | サルトリア・フアーマシユーテイカルズ・エル・エル・シー | Method for the treatment of diabetes and composition of probucol derivatives |
WO2008130718A1 (en) | 2007-04-23 | 2008-10-30 | Atherogenics, Inc. | Sulfonamide containing compounds for treatment of inflammatory disorders |
WO2010106436A2 (en) | 2009-03-18 | 2010-09-23 | Resverlogix Corp. | Novel anti-inflammatory agents |
KR102503695B1 (en) | 2013-02-28 | 2023-02-23 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | Methods and compositions for mobilizing stem cells |
US10947311B2 (en) | 2015-11-20 | 2021-03-16 | The Board Of Trustees Of The Leland Stanford Junior University | VCAM-1 mediated methods and compositions for treating aging-associated impairments |
CN110452877A (en) * | 2018-05-07 | 2019-11-15 | 北京吉尚立德生物科技有限公司 | A kind of cultural method of lung cancer solid tumor primary cell |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3929913A1 (en) * | 1989-09-08 | 1991-04-04 | Hoechst Ag | 4-HYDROXYTETRAHYDROPYRAN-2-ONE AND THE CORRESPONDING DIHYDROXYCARBONSAEUREDERIVATES, SALTS AND ESTERS, PROCESS FOR THEIR PREPARATION, THEIR USE AS A MEDICAMENT, PHARMACEUTICAL PREPARATES AND PREPARED PRODUCTS |
FR2704224B1 (en) * | 1993-04-20 | 1995-08-25 | Adir | New acids and substituted isobutyric phenoxy esters. |
ID23877A (en) * | 1997-05-14 | 2000-05-25 | Atherogenics Inc | COMPOUNDS AND METHODS FOR INCOME OF VCAM-1 EXPRESSION |
ATE326014T1 (en) * | 1998-11-09 | 2006-06-15 | Atherogenics Inc | METHOD AND COMPOSITIONS FOR REDUCING PLASMA CHOLESTEROL LEVELS |
-
2001
- 2001-03-21 EP EP01920617A patent/EP1289944A2/en not_active Withdrawn
- 2001-03-21 AU AU4765101A patent/AU4765101A/en active Pending
- 2001-03-21 WO PCT/US2001/009049 patent/WO2001070757A2/en active Application Filing
- 2001-03-21 AU AU2001247651A patent/AU2001247651B2/en not_active Ceased
- 2001-03-21 JP JP2001568958A patent/JP2003528109A/en not_active Withdrawn
- 2001-03-21 CA CA002403823A patent/CA2403823A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2403823A1 (en) | 2001-09-27 |
WO2001070757A2 (en) | 2001-09-27 |
WO2001070757A3 (en) | 2002-03-14 |
JP2003528109A (en) | 2003-09-24 |
EP1289944A2 (en) | 2003-03-12 |
AU2001247651B2 (en) | 2007-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60111076D1 (en) | Thioether substituierte imidazochinoline | |
GB2385524B (en) | Compositions and methods of use for extracts of magnoliaceae | |
HUP0004592A3 (en) | Compounds and methods for the inhibition of the expression of vcam-1 | |
EP1572890A4 (en) | Slc7s as modifies of the p53 pathway and methods of use | |
AU2003295801A8 (en) | Modulation of hif1alpha and hif2alpha expression | |
AU2001284690A1 (en) | Compositions exhibiting synergistic inhibition of the expression and/or activityof cyclooxygenase-2 | |
HUP0302297A3 (en) | Substituted thioacetamides and pharmaceutical compositions containing them | |
AU4765101A (en) | Thioketals and thioethers for inhibiting the expression of vcam-1 | |
AU5073101A (en) | Lipid composition and use thereof | |
AU1334602A (en) | Osteopontin-coated surfaces and methods of use | |
AU6395201A (en) | Tumour suppressor and uses thereof | |
IL157975A0 (en) | Synthetic derivatives of 21-butenyl and related spinosyns | |
EP1503749A4 (en) | Methionine aminopeptidase-2 inhibitors and methods of use thereof | |
AU7501801A (en) | Composition and method for enhancing elasticity of tissue | |
PL365582A1 (en) | Use of salmeterol and fluticasone propionate combination | |
EP1309552A4 (en) | Compounds and inhibitors of phospholipases | |
AU2002363938A8 (en) | Methods and use of motoneuronotropic factors | |
EP1263935A4 (en) | Scytonemin and methods of using thereof | |
AU7402201A (en) | Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments | |
AU5565401A (en) | Materials and methods for the treatment of depression | |
AU2003296871A8 (en) | Point feeder and use of point feeder | |
IL140555A0 (en) | Conjugates of alliinase and pharmaceutical compositions comprising them | |
HK1054306A1 (en) | Application of cosmetics | |
EP1392460A4 (en) | Hydrogenfluorides of aminosilanols and their use | |
GB2363981B (en) | Assemblies of Case-holder and Case |